CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration

Nature Communications
Taeyoung KooJin-Soo Kim

Abstract

LbCpf1, derived from Lachnospiraceae bacterium ND2006, is a CRISPR RNA-guided endonuclease and holds promise for therapeutic applications. Here we show that LbCpf1 can be used for therapeutic gene editing in a mouse model of age-related macular degeneration (AMD). The intravitreal delivery of LbCpf1, targeted to two angiogenesis-associated genes encoding vascular endothelial growth factor A (Vegfa) and hypoxia inducing factor 1a (Hif1a), using adeno-associated virus, led to efficient gene disruption with no apparent off-target effects in the retina and retinal pigment epithelium (RPE) cells. Importantly, LbCpf1 targeted to Vegfa or Hif1a in RPE cells reduced the area of laser-induced choroidal neovascularization as efficiently as aflibercept, an anti-VEGF drug currently used in the clinic, without inducing cone dysfunction. Unlike aflibercept, LbCpf1 targeted to Vegfa or Hif1a achieved a long-term therapeutic effect on CNV, potentially avoiding repetitive injections. Taken together, these results indicate that LbCpf1-mediated in vivo genome editing to ablate pathologic angiogenesis provides an effective strategy for the treatment of AMD and other neovascularization-associated diseases.

References

Mar 24, 2007·Science·Rodolphe BarrangouPhilippe Horvath
Apr 29, 2008·The New England Journal of Medicine·Albert M MaguireJean Bennett
Apr 29, 2008·The New England Journal of Medicine·James W B BainbridgeRobin R Ali
Jan 20, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Amit C NathwaniAndrew M Davidoff
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Oct 25, 2012·The Journal of Clinical Investigation·Toshihide KuriharaMartin Friedlander
Jan 5, 2013·Science·Le CongFeng Zhang
Jan 5, 2013·Science·Prashant MaliGeorge M Church
Jan 31, 2013·Nature Biotechnology·Seung Woo ChoJin-Soo Kim
Feb 7, 2013·ELife·Martin JinekJennifer Doudna
Apr 13, 2013·Pharmacotherapy·Lily K Cheung, Angie Eaton
Sep 17, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Leah C ByrneJohn G Flannery
Jun 5, 2015·Nature Reviews. Cancer·Francisco J Sánchez-Rivera, Tyler Jacks
Apr 21, 2016·Nature·Ines FonfaraEmmanuelle Charpentier
Jun 4, 2016·Investigative Ophthalmology & Visual Science·Sang Jun ParkSe Joon Woo
Jun 9, 2016·Nature Biotechnology·Daesik KimJin-Soo Kim
Jun 9, 2016·Nature Biotechnology·Junho K HurJin-Soo Kim
Jun 28, 2016·Nature Biotechnology·Benjamin P KleinstiverJ Keith Joung
Jul 2, 2016·Investigative Ophthalmology & Visual Science·Sandy S C HungAlex W Hewitt
Aug 27, 2016·Briefings in Functional Genomics·Taeyoung Koo, Jin-Soo Kim
Oct 22, 2016·Investigative Ophthalmology & Visual Science·Glenn YiuZeljka Smit-McBride
Dec 6, 2016·Nature Biotechnology·Bernd ZetscheFeng Zhang
Dec 20, 2016·Nature Methods·Hui K KimHyongbum Kim
Dec 23, 2016·Nature Reviews. Drug Discovery·Christof FellmannJacob E Corn
Jan 31, 2017·Molecular Therapy. Nucleic Acids·Wei-Jing DaiXiao-Jie Lu
Feb 22, 2017·Nature Communications·Eunji KimJin-Soo Kim
Mar 16, 2017·Nature Communications·Wenhan YuZhijian Wu
Apr 20, 2017·Frontiers in Neuroscience·G Alex OchakovskiM Dominik Fischer
Jul 26, 2017·Nature Communications·Xionggao HuangHetian Lei

❮ Previous
Next ❯

Citations

Nov 30, 2018·Genes·David J JiangStephen H Tsang
Dec 21, 2019·Journal of Medical Genetics·Daniela BenatiAlessandra Recchia
Aug 25, 2020·The CRISPR Journal·Lavina Sierra TayPrashant Mali
Jul 3, 2020·International Journal of Molecular Sciences·Olivia RastoinMaeva Dufies
Mar 12, 2020·Animal Cells and Systems·Hyunji LeeKyoungmi Kim
May 18, 2020·Current Diabetes Reports·Jiang-Hui WangGuei-Sheung Liu
Sep 27, 2020·Genes·Ilayda AtesRenee N Cottle
Dec 27, 2018·International Ophthalmology Clinics·Weijie Violet LinChristina Y Weng
Mar 19, 2019·Annual Review of Biochemistry·Daesik KimJin-Soo Kim
Aug 29, 2020·Translational Vision Science & Technology·Yu Qiang SohAnna Cheng Sim Tan
Nov 3, 2020·Frontiers in Cellular Neuroscience·Fan LiAlex W Hewitt
Oct 7, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Andreas Braae HolmgaardThomas J Corydon
Jul 1, 2020·Advanced Drug Delivery Reviews·Wenhan Yu, Zhijian Wu
Jan 6, 2021·Asia-Pacific Journal of Ophthalmology·David XuAllen C Ho
Feb 11, 2021·Pharmaceutics·Sanna KoponenSeppo Ylä-Herttuala
Feb 18, 2021·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Xiangjun HeBo Feng
Jul 11, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Fan-Li LinGuei-Sheung Liu
Apr 13, 2021·The Keio Journal of Medicine·Deokho LeeToshihide Kurihara
Jun 25, 2021·Archives of Pharmacal Research·Myeonghoon Song, Taeyoung Koo
Apr 7, 2021·Ophthalmic Genetics·Mayank BansalDebojyoti Chakraborty
Mar 5, 2020·Molecular Therapy. Methods & Clinical Development·Sook Hyun ChungGlenn Yiu
Jul 20, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·A-Rum YoonChae-Ok Yun
Jan 17, 2020·Ophthalmic Research·Qiu-Yang ZhangBiao Yan

❮ Previous
Next ❯

Datasets Mentioned

BETA
SRP129908

Methods Mentioned

BETA
transfection
ELISA
PCR

Software Mentioned

OFFinder
Image J
Cas

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.